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ABSTRACT 1 
Introduction: The formation of anti-infliximab antibodies (ATI) is associated with loss of response and 2 
adverse events in patients with inflammatory bowel diseases (IBD), leading to the introduction of ATI 3 
monitoring for guiding treatment adjustments. However, a lack of standardization amongst current 4 
available assays exists, hampering comparison of results from different studies. This study aimed to 5 
improve the harmonization of clinically validated ATI ELISAs by introducing a monoclonal anti-6 
infliximab antibody (MA-IFX). 7 
Methods: A panel of MA-IFX was evaluated as calibrator in the 1st generation ATI ELISA. After 8 
selection of one MA-IFX, assay conditions were optimized and biotin-streptavidin enhanced 9 
detection of bound infliximab was introduced. The novel 2nd generation ELISA was used for re-10 
analysis of 127 serum samples from a cohort of 12 IBD patients, previously identified as ATI positive.  11 
Results: Out of 55 MA-IFX, MA-IFX10F9 was selected as calibrator in the ATI ELISA. After optimization 12 
of the assay conditions, a 4-fold improvement in sensitivity was obtained. Re-analysis of 127 serum 13 
samples revealed that in five out of 12 patients (46%) ATI were detected at least one time point 14 
earlier with the 2nd generation ELISA compared to the 1st generation ELISA. In one patient, the 2nd 15 
generation ELISA allowed to detect ATI before the re-initiation of IFX after a drug holiday. 16 
Conclusions: In addition to the improved sensitivity and specificity of the 2nd generation ATI ELISA, 17 
MA-IFX10F9 can serve as a universal calibrator to achieve assay harmonization. Moreover, the 18 
superiority of the 2nd generation assay in analyzing serum of re-starters was demonstrated.  19 
Key words: infliximab; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; immunology; 20 
inflammatory bowel diseases 21 
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INTRODUCTION 1 
The introduction of biological drugs targeting tumor necrosis factor (anti-TNF), like infliximab (IFX), a 2 
chimeric monoclonal antibody, has redefined the treatment of chronic inflammatory diseases such as 3 
rheumatoid arthritis and inflammatory bowel diseases (IBD).1 Their use led to a considerable 4 
improvement in therapy outcome, much needed in clinical practice. However, inherently related to 5 
the nature of these drugs, they are often recognized by the immune system as non-self and as a 6 
result elicit the formation of anti-drug antibodies (ADA). This immune response leads in numerous 7 
cases to loss of response.2-6 However, in some patients ADA only appear transiently not leading to 8 
clinical loss of response, as was observed in a retrospective study with 90 IBD patients on IFX 9 
therapy.7  10 
The management of patients under biological drugs used to be strictly empirical. Dose adaptations 11 
were performed according to the patient’s symptoms. Drug was switched in patients with persistent 12 
loss of response. With the latest knowledge regarding therapeutic drug monitoring, therapy has 13 
become more personalized and efficient.8 Multiple clinical studies have demonstrated a link between 14 
trough concentrations of IFX, which is the drug concentration just before the next dose 15 
administration, and clinical response in patients with IBD.9,10 Low or undetectable trough 16 
concentrations correlate with reduced drug efficacy, whilst adequate trough concentrations correlate 17 
with sustained response to IFX. Undetectable trough concentrations are often caused by a faster 18 
clearance of drug due to complex formation with ADA, hence monitoring of ADA is clinically relevant. 19 
Trough concentrations and ADA data were merged into treatment algorithms to aid clinical decision 20 
making.9,11-13  21 
Different assays exist for measurement of IFX and anti-infliximab antibodies (ATI), but while for drug 22 
concentration assays, the drug itself can be used as calibrator, a universal ATI standard doesn’t exist. 23 
Hence, ATI are reported as arbitrary units towards (monospecific) polyclonal rabbit anti-IFX 24 
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antibodies (ELISA14-16) or as titration value (ELISA17, radio-immunoassay18-20, homogeneous mobility 1 
shift assay21).  2 
A 1st generation ATI ELISA was developed in the laboratory for Therapeutic and Diagnostic Antibodies 3 
(KU Leuven, Leuven, Belgium) using a monospecific rabbit polyclonal anti-IFX (pAb-IFX) calibrator. 14 4 
This assay was clinically validated using sera of IFX treated IBD patients. In a round robin experiment 5 
the assay was compared with two other available ATI assays and, although reported values differed 6 
and were not interchangeable, a good correlation was found between all three assays.22 However, 7 
the use of a polyclonal antibody calibrator is limited due to batch-to-batch variation inherent to their 8 
polyclonal nature.  9 
The aim of this work was to develop a universal calibrator that could be used in different assay 10 
formats to harmonize anti-IFX antibody titers in IBD patients. This was done by introducing a 11 
monoclonal anti-IFX antibody (MA-IFX) as a calibrator in the current “in-house” developed ATI ELISA 12 
and through optimization of the assay conditions. We hypothesized that the newly developed assay 13 
could detect ATI earlier resulting from an increased sensitivity. Therefore, a consecutive number of 14 
samples were selected from a cohort of IBD patients previously identified to be ATI positive and were 15 
re-analyzed with both versions of the assay.  16 
MATERIALS AND METHODS 17 
Bovine serum albumin (BSA), horseradish peroxidase (HRP), polyoxyethylene (20) sorbitan 18 
monooleate, sulphuric acid (H2SO4), sucrose and citric acid were purchased from Sigma-Aldrich 19 
(Steinheim, Germany). EDTA was purchased from Chem-Lab NV (Zedelgem, Belgium) and VWR 20 
International (Haasrode, Belgium) delivered disodium hydrogen phosphate dihydrate (Na2HPO4 21 
·2H2O) and sodium chloride (NaCl). Potassium dihydrogen phosphate (KH2PO4) and Sulfo-NHS-LC-22 
Biotin were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). HRP-conjugated 23 
streptavidin was purchased from IBL International GmbH (Hamburg, Germany). H2O2 was purchased 24 
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from Merck (Darmstadt, Germany) and o-phenylenediamine and potassium chloride (KCl) from Acros 1 
Organics (Geel, Belgium).  2 
IFX was purchased as Remicade from Janssen Biologics B.V. (Leiden, the Netherlands). 3 
Blood samples 4 
Blood samples of patients with IBD were drawn at the infusion unit of the Department of 5 
Gastroenterology, UZ Leuven, using the “BD Vacutainer SST II Advance tube” (BD Biosciences, 6 
Franklin Lakes, NJ, USA), containing a gel separator and clot activator. After an incubation time of 30 7 
min, serum was prepared by centrifugation (10 min, 1960 g, RT) and stored at -20°C.  8 
Introduction of a MA-IFX calibrator in the ATI ELISA 9 
A panel of in-house developed monoclonal anti-IFX antibodies, which was generated, produced and 10 
characterized as described in Van Stappen et al.23, was evaluated as calibrator in the 1st generation 11 
ATI ELISA.22 Briefly, 96-well plates were coated overnight with IFX and were blocked with 1% BSA in 12 
phosphate buffered saline (PBS; 140 mM NaCl, 8 mM Na2HPO4·2H2O, 2.7 mM KCl and 1.5 mM 13 
KH2PO4). Dose-response curve of MA-IFX calibrators were applied on the plate and HRP-labeled IFX 14 
was added for detection of bound MA-IFX. Next, plates were developed using 400 µg/mL o-15 
phenylenediamine and 0.003% H2O2 in 0.1 M sodium citrate, 0.2 M disodium phosphate buffer pH 5 16 
(citrate buffer) and the reaction was stopped with 4 M H2SO4. The absorbance was measured at 490 17 
nm with an ELx808 Absorbance Microplate Reader (BioTek Instruments Inc., Winooski, VT, USA) and 18 
the MA-IFX  dose-response curves were analyzed using nonlinear regression with Graphpad Prism 5.0 19 
(Graphpad Software, San Diego, CA, USA). One MA-IFX was selected for further assay optimization. 20 
Optimization of the ATI assay using biotin-streptavidin enhanced detection 21 
IFX was labeled with Sulfo-NHS-LC-Biotin according to the manufacturer’s instructions. IFX was gently 22 
mixed with a 20-fold molar excess of biotin solution for 30min at room temperature on a rotator and 23 
dialyzed overnight against PBS. The conjugate was sterilized through filtration and stored at 4°C. The 24 
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performance of biotin-labeled IFX combined with HRP-labeled streptavidin for detection of bound 1 
MA-IFX was evaluated in the ATI ELISA. Briefly, 96-well plates were coated with IFX and free binding 2 
places blocked with PBS 1% BSA. Next, a dose-response curve of the selected MA-IFX was applied on 3 
the plate, followed by the addition of biotin-labeled IFX as primary conjugate and HRP-labeled 4 
streptavidin as secondary conjugate. Plates were developed using o-phenylenediamine and H2O2 and 5 
the reaction stopped with H2SO4. The absorbance was measured at 490 nm and dose-response 6 
curves analyzed using nonlinear regression with Graphpad Prism 5.0. Dose-response curves of biotin-7 
labeled IFX were compared to dose-response curves of HRP-labeled IFX. In addition, different assay 8 
parameters such as the incubation method, time and temperature and the coating concentration 9 
were optimized to maximize the assay performance and minimize the assay execution time.  10 
Lower limit of quantification, accuracy and imprecision  11 
The cut-off value of the assay was determined using 30 anti-TNF naïve IBD patient samples. The 12 
samples were applied in a 1:20 dilution and the mean optical density obtained with patient samples 13 
plus three standard deviations was compared to the optical density of the MA-IFX10F9 calibrator 14 
concentration at 0.078 ng/mL. Accuracy and imprecision were determined by preparing 5 quality 15 
control samples of MA-IFX10F9 in PTAE (PBS 0.1% BSA; 0.002% polyoxyethylene (20) sorbitan 16 
monooleate; 5 mM EDTA) (5 ng/mL – 10 ng/mL – 20 ng/mL – 50 ng/mL – 100 ng/mL). The quality 17 
control samples were diluted 1:20, 1:40, 1:80, 1:160 and six replicates were applied per plate. The 18 
experiment was performed in triplicate. All samples were interpolated from the MA-IFX10F9 dose-19 
response curve by nonlinear regression analysis with Graphpad Prism 5.0. 20 
Re-analysis of IBD patient samples 21 
Twelve IBD patients, previously identified as ATI positive using the 1st generation ATI ELISA and 22 
among whom nine patients had Crohn’s disease and three ulcerative colitis, were selected for re-23 
assessment with the 1st and 2nd generation ATI ELISA. In total, 127 serum samples were analyzed with 24 
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a median of 11 (range 5 – 15) consecutive serum samples per patient. Patient samples were 1 
interpolated from the dose-response curve using Graphpad Prism 5.0.  2 
Response to treatment 3 
Clinical data were retrospectively collected to determine whether patients were still receiving IFX 4 
one year after initial ATI development, with or without a treatment intervention by the treating 5 
clinician. An intervention was defined as either surgery, initiation of combo-therapy or a dose 6 
adaptation, which included a dose increase of IFX to 10 mg/kg, a shortening of the interval between 7 
two drug administrations or a combination of both.  8 
Ethical considerations 9 
This study was approved by the Ethical Committee UZ Leuven in the framework of the Flemish 10 
inheritance study for Crohn and colitis (B322201213950/S53684). Informed consent was provided by 11 
all patients.  12 
RESULTS 13 
Selection of MA-IFX10F9 for use in the ATI ELISA 14 
The ability of 55 MA-IFX belonging to nine clusters to function as a calibrator in the ATI ELISA setup 15 
was evaluated.23 Based upon the ability to crosslink coated IFX with HRP-labeled IFX, high specificity 16 
and high affinity for IFX, MA-IFX10F9 was selected for further use in the ATI ELISA. MA-IFX10F9 is a 17 
high affinity, inhibitory IgG1 anti-IFX antibody with ĸ light chain that binds to the Fab fragment of IFX.  18 
Optimization of the ATI assay using biotin-streptavidin enhanced detection 19 
Using MA-IFX10F9 as a calibrator, biotin-labeled IFX combined with streptavidin-HRP for the 20 
detection of bound ATI was compared with HRP-labeled IFX. The calibrator dose-response curve of 21 
biotin-streptavidin enhanced ATI detection was found to be more sensitive than HRP-based ATI 22 
detection. In addition, different assay parameters were optimized including the incubation method, 23 
time and temperature of the different assay steps and the coating concentration, further clarified in 24 
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Table 1. Finally, a 4-fold improvement in the sensitivity of the novel 2nd generation ATI ELISA was 1 
obtained, when compared to the previously used 1st generation ATI ELISA, shown in Figure 1. The 2 
increased sensitivity and the introduction of MA-IFX10F9 as a calibrator allow to report ATI 3 
concentrations from patient samples in ng/mL equivalents MA-IFX10F9 instead of µg/mL equivalents 4 
pAb-IFX. 5 
Lower limit of quantification, accuracy and imprecision  6 
The use of MA-IFX10F9 as a calibrator in the ATI assay yielded a nonlinear dose-response curve in the 7 
range 0.078 ng/mL – 5 ng/mL. The cut-off value of the assay was determined using 30 anti-TNF naïve 8 
serum samples. The mean OD of the samples was 0.014 with a standard deviation of 0.008, giving a 9 
value of 0.039, which was lower than the OD (0.083) of the lowest point of the calibrator dose-10 
response curve. Taking into account the 1:20 dilution, the assay cut-off was set at 1.6 ng/mL 11 
equivalents MA-IFX10F9. The assay complied with the requirements for accuracy (mean recovery 12 
ranging from 96% to 102%) and imprecision (coefficient of variation ranging from 7% to 13%) for all 13 
quality control samples tested. As 5 ng/mL was still accurately detected with a recovery of 98% and 14 
coefficient of variation of 13%, the limit of quantification was set at 5 ng/mL equivalents MA-15 
IFX10F9. 16 
Re-analysis of IBD patient samples 17 
One hundred twenty seven patient samples were re-analyzed with both the 1st and 2nd generation 18 
ATI ELISA. Eleven out of 12 ATI positive patients had one or more time points with undetectable IFX 19 
concentrations whilst in one patient IFX was detectable in all serum samples.  20 
Nine out of 127 samples (7%) were ATI positive in the 1st generation ELISA and negative in the 2nd 21 
generation ELISA. All nine samples came from one patient (patient 12, Figure 2), of which the first 22 
sample was an anti-TNF naïve sample. In 57/127 samples (45%) ATI were detected simultaneously 23 
with both ELISAs, while 14/127 samples (11%) were ATI positive in the 2nd generation ELISA and 24 
negative in the 1st generation ELISA. In 5/12 patients (46%), ATI were detected one or two time 25 
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points earlier with the 2nd generation ELISA compared to the 1st generation ELISA (patient 1 to 5, 1 
Figure 2). Of those, one patient restarted IFX therapy after a drug holiday of six years and detectable 2 
ATI concentrations were found using the 2nd generation ATI ELISA just prior to the first infusion of re-3 
initiation of IFX (patient 5, Figure 2) whereas with the 1st generation ATI ELISA, ATI were only 4 
detectable prior to the second infusion of IFX.  In Figure 2, the course of ATI formation in all 12 5 
patients is visualized.  6 
Response to treatment 7 
One year after first ATI detection, five out of five patients (patient 1, 2, 4, 8 & 10; Figure 2) with 8 
transient ATI were still receiving IFX therapy following an intervention. Three patients (patient 1, 2 & 9 
4) required an interval reduction (from 8 to 4 weeks) and dose intensification (5 mg/kg to 10 mg/kg) 10 
to overcome the ATI response. In addition, patient 2 received prophylactic therapy and addition of an 11 
immunosuppressant. Patient 8 only required interval shortening from 8 to 7 weeks. Patient 10 12 
underwent a right hemicolectomy, allowing him/her to continue IFX therapy without interval 13 
shortening or dose adaptation. All patients who persistently developed ATI lost clinical response to 14 
IFX and were consequently switched to other (anti-TNF) drugs, five out of six within one year after 15 
first ATI detection. Of those, one patient suffered from an acute infusion reaction at the second 16 
infusion of re-initiation of IFX after a drug holiday of six years. The patient wherein no ATI were 17 
detected with the 2nd generation ATI ELISA still received IFX after one year and was doing clinically 18 
well.  19 
DISCUSSION 20 
The measurement of ADA is challenging and can be performed with many different techniques (i.e. 21 
ELISA14-17, radio-immunoassay18-20, homogeneous mobility shift assay21). Bridging ELISA’s and radio-22 
immunoassays are commonly used, but have the disadvantage that ADA cannot be detected in the 23 
presence of drug. Drug sensitivity can be reduced using sample pretreatment steps such as acid 24 
dissociation, which is used for instance in the pH-shift-anti-idiotype antigen binding test (PIA).19 25 
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Nevertheless, whether the measurement of ADA in complex with drug is clinically relevant is much 1 
debated. In a recent study in 99 rheumatoid arthritis patients treated with adalimumab, the 2 
detection of anti-adalimumab antibodies (ATA) in complex with adalimumab using the PIA assay was 3 
not linked to a reduction in clinical response, while free ATA measured with the drug sensitive 4 
antigen binding test was correlated.24 However, the likelihood of patients with complexed ATA to 5 
have detectable free ATA during subsequent follow-up was higher than for patients without 6 
complexed ATA. Furthermore, the clinical equivalence of different assays was investigated in a post-7 
hoc analysis of a randomized controlled trial.25 In this study it was seen that different assays, 8 
including a drug sensitive homogeneous mobility shift assay, did not largely differ in predicting the 9 
best treatment strategy at time of loss of response to IFX therapy.  10 
Besides assay dependent shortcomings and their clinical relevancy, a major issue currently 11 
acknowledged by experts is the fact that different techniques are not reporting ATI in the same unit. 12 
While some assays express ATI as arbitrary units towards an antibody calibrator (ELISA14-16), other 13 
assays make use of titration values (ELISA17, radio-immunoassay18-20, homogeneous mobility shift 14 
assay21), inhibiting a direct comparison of reported ATI values between different assays.22,26 15 
Harmonization of ATI assays will be indispensable to facilitate and generalize clinical decision making 16 
at time of loss of response to IFX. Comparison studies aiming to define assay conversion factors and 17 
universal calibrators may serve as a stepping stone to this ambitious target.  18 
Polyclonal anti-IFX antibodies as calibrator are not first choice as they cross-react with other anti-TNF 19 
drugs and introduce variability due to batch-to-batch variation inherent to their polyclonal nature. 20 
The introduction of a highly specific monoclonal anti-IFX antibody, MA-IFX10F9, offers the advantage 21 
of continuous production, thereby limiting batch-to-batch variation. In addition, the initial protocol 22 
of the 1st generation ATI ELISA was optimized to improve the assay speed, performance and 23 
specificity. Furthermore, titration discrepancies frequently observed with the 1st generation ATI ELISA 24 
are reduced with the 2nd generation ATI ELISA. 25 
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The improved assay sensitivity of the 2nd generation ATI ELISA resulted in an earlier detection of ATI 1 
in 5/12 patients (46%) compared to the 1st generation ELISA. One of these patients restarted IFX 2 
therapy after a drug holiday of six years and the 1st generation ATI ELISA detected ATI only prior to 3 
the second infusion of IFX after re-initiation, during which the patient developed an acute infusion 4 
reaction. The 2nd generation ATI ELISA detected ATI already prior to the first infusion of re-initiation 5 
of IFX. This example clearly demonstrates the superiority of the 2nd generation ELISA in patients 6 
restarting IFX after a drug holiday.  7 
Our results also indicate an enhanced assay specificity since one patient was reclassified as ATI 8 
negative with the 2nd generation ELISA that was initially classified as ATI positive with the 1st 9 
generation ELISA. This patient was found to have detectable IFX trough concentrations over the 10 
course of time, most likely indicative of an aspecific response in the 1st generation ELISA.  11 
Retrospectively, it was seen that five out of five patients with transient ATI still received IFX one year 12 
after the first ATI detection, while IFX treatment was discontinued in all patients with persistent ATI 13 
development, five out of six within one year after initial ATI detection – reconfirming previous 14 
findings that ATI development may be overcome upon an intervention and not necessarily lead to 15 
clinical loss of response.7,24 Follow-up of ATI in consecutive serum samples is therefore advised. 16 
In conclusion, we have introduced MA-IFX10F9, a monoclonal anti-IFX antibody that can serve as a 17 
universal calibrator to achieve harmonization of ATI titers. In addition, we have increased the 18 
sensitivity and specificity of the ATI ELISA resulting in an earlier detection of ATI formation in a 19 
considerable amount of ATI positive IBD patients. Early ATI detection can improve timely treatment 20 
decisions to prevent loss of response and allows choosing the most cost-efficient treatment option in 21 
case of loss of response. In patients restarting IFX after a drug holiday, ATI measurements are crucial 22 
to avoid the risk of adverse events such as infusion reactions and unnecessary treatment costs.   23 
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FIGURE LEGENDS 
FIGURE 1. Dose-response curves using the pAb-IFX calibrator in the 1st generation ATI ELISA (left) and 
the MA-IFX10F9 calibrator in the 2nd generation anti-infliximab antibody ELISA (right). pAb-IFX, 
polyclonal anti-infliximab antibody; ATI, anti-infliximab antibodies; MA-IFX, monoclonal anti-
infliximab calibrator; OD, optical density 
FIGURE 2. Re-analysis of inflammatory bowel diseases patient samples using the 1st (dashed line, left 
y-axis) and 2nd generation (solid line, right y-axis) ATI ELISA. ATI concentrations are reported in µg/mL 
equivalents pAb-IFX and ng/mL equivalents MA-IFX10F9 in the 1st and 2nd generation ATI ELISA, 
respectively. IFX concentrations are reported in µg/mL (dotted line, left y-axis). Time points marked 
with an asterisk indicate clinical interventions and double asterisks unavailability of sample. In total, 
71/117 samples (61%) were found ATI positive in the 2nd generation ELISA, while the 1st generation 
ELISA detected ATI in only 57/117 (49%). In patients 1 to 5, first ATI detection was seen one or two 
time points earlier with the 2nd generation ELISA than with the 1st generation ELISA (arrows). Of 
those, patient 5 was reinitiated with IFX after a drug holiday of 6 years, despite detectable ATI at 
restart using the 2nd generation ATI ELISA (arrow). In patient 12, ATI were detected in multiple 
consecutive samples with the 1st generation ELISA whereas the 2nd generation ELISA did not detect 
ATI. ATI, anti-infliximab antibodies; pAb-IFX, polyclonal anti-infliximab antibody; MA-IFX, monoclonal 
anti-infliximab antibody; IFX, infliximab. 
 
